Showing results (1-10 of 41) with videos related to
Sort By:
Pageof 5
Gastroenterologia Y Hepatologia|April 18, 2009
[Validation of the Reflux Disease Questionnaire (RDQ) and Gastrointestinal Impact Scale (GIS) in patients with gastroesophageal reflux disease in the Spanish population]Javier Nuevo, Mónica Tafalla, Javier ZapardielAnnals of the Rheumatic Diseases|December 20, 2013
Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practiceAngel Lanas, Maarten Boers, Javier NuevoERJ Open Research|October 21, 2020
Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study designJørgen Vestbo, Christer Janson, Javier Nuevo, et al.World Journal of Nephrology|May 26, 2017
Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based studySylvie Perreault, Javier Nuevo, Scott Baumgartner, et al.Atencion Primaria|March 9, 2011
[Use of health resources and loss of productivity in gastroesophageal reflux disease: results of a cross-sectional study in a primary care setting in Spain]Javier Nuevo, Mónica Tafalla, Javier Zapardiel, et al.Gastroenterologia Y Hepatologia|July 14, 2010
[Study of the clinical profile and management of patients with gastroesophageal reflux disease in primary care in Spain]Mónica Tafalla, Javier Nuevo, Javier Zapardiel, et al.BMC Pulmonary Medicine|December 19, 2021
Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)Eva Martínez-Moragón, Ismael García-Moguel, Javier Nuevo, et al.International Journal of Chronic Obstructive Pulmonary Disease|May 29, 2018
The impacts of morning, daytime, and nighttime symptoms on disease burden in real-world patients with COPDAnna Muñoz, Mark Small, Robert Wood, et al.Journal of Medical Economics|October 6, 2018
The economic burden of uncontrolled gout: how controlling gout reduces costNatalia M Flores, Javier Nuevo, Alyssa B Klein, et al.Journal of Medical Economics|January 21, 2020
Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in SpainAntoni Sicras-Mainar, Margarita Capel, Ruth Navarro-Artieda, et al.Pageof 5